A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting now · Phase 1/Phase 2

Conditions studied: Relapsed or Refractory Multiple Myeloma

In brief

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).

Key facts

Study ID

NCT07116616

Run by

ModernaTX, Inc.

People needed

166

Starts

2025-09-30

Expected to finish

2032-06-17

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Hospital — Birmingham, Alabama, United States (enrolling)
• UCSF — San Francisco, California, United States (enrolling)
• Emory University Hospital — Atlanta, Georgia, United States (enrolling)
• Mass General Brigham — Boston, Massachusetts, United States (enrolling)
• Tisch Cancer Institute at Mount Sinai — New York, New York, United States (enrolling)
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States (enrolling)
• Atrium Health Levine Cancer Institute — Charlotte, North Carolina, United States (enrolling)
• Penn Medicine — Philadelphia, Pennsylvania, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• The Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.